Intervention: Saracatinib
Trial phase: Phase 2
SMILES: CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity.

saracatinib: Given orally
Eligibility criteria:
Inclusion Criteria:

Leukocytes >= 3,000/mcL

Histologically or cytologically confirmed soft tissue sarcoma including, but not limited to any of:

Malignant fibrous histiocytoma
Fibrosarcoma - non infantile
Leiomyosarcoma - not uterine
Liposarcoma
Non-rhabdomyosarcoma soft tissue sarcoma
Rhabdomyosarcoma, not otherwise specified
Carcinosarcoma of the uterus
Dermatofibrosarcoma
Endometrial stromal sarcoma
Leiomyosarcoma - uterus

Recurrent or locally advanced or metastatic disease

No more than two prior lines of chemotherapy for metastatic disease (not including adjuvant chemotherapy)

Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan

Target measurable lesion must not have been in previous radiation portal, unless progression of this lesion after radiotherapy has been documented
ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
Life expectancy > 12 weeks
Recovered from all prior therapy
Platelet count >= 100,000/mcL
Hemoglobin > 9 g/dL
Total bilirubin =< 1.25 times upper limit of normal (ULN)
AST and ALT =< 3 times ULN
Creatinine =< 1.5 times ULN OR creatinine clearance >= 50 mL/min
Urine protein:creatinine ratio =< 1.0 OR 24-hour urine protein < 1,000 mg
ANC >1,500/mcL
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 8 weeks after completion of study therapy
No history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530
No QTc prolongation (defined as a QTc interval >= to 460 msecs) or other significant ECG abnormalities
No poorly controlled hypertension (i.e., systolic blood pressure (BP) >= 140 mm Hg, or diastolic BP >= 90 mm Hg)

No condition that impairs a patient's ability to swallow AZD0530 tablets, including any of the following:

Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
Prior surgical procedures affecting absorption
Active peptic ulcer disease

Exclusion Criteria:

At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

No intercurrent cardiac dysfunction including, but not limited to, any of the following:

Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
No history of ischemic heart disease, including myocardial infarction
No uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
More than 4 weeks since prior radiotherapy
More than 7 days since prior and no concurrent prohibited CYP3A4-active agents or substances
No other concurrent investigational agents or commercial agents or therapies
No concurrent combination antiretroviral therapy for HIV-positive patients
No known brain metastases